Comment on

• Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients.

  Calmus Y, Scheele JR, Gonzalez-Pinto I, Jaurrieta EJ, Klar E, Pageaux GP, Scudamore CH, Cuervas-Mons V, Metselaar HJ, Prestele H, Girault D. Calmus Y, et al. Liver Transpl. 2002 Feb;8(2):123-31. doi: 10.1053/jlts.2002.30882. Liver Transpl. 2002. PMID: 11862588 Clinical Trial.
• Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial.

  Neuhaus P, Clavien PA, Kittur D, Salizzoni M, Rimola A, Abeywickrama K, Ortmann E, Chodoff L, Hall M, Korn A, Nashan B; CHIC 304 International Liver Study Group. Neuhaus P, et al. Liver Transpl. 2002 Feb;8(2):132-42. doi: 10.1053/jlts.2002.30302. Liver Transpl. 2002. PMID: 11862589 Clinical Trial.